Marion Chevrier

ORCID: 0000-0002-9157-8312
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Single-cell and spatial transcriptomics
  • Breast Cancer Treatment Studies
  • Immune Cell Function and Interaction
  • Ovarian cancer diagnosis and treatment
  • Lymphoma Diagnosis and Treatment
  • T-cell and B-cell Immunology
  • Immunotherapy and Immune Responses
  • Cancer Genomics and Diagnostics
  • CNS Lymphoma Diagnosis and Treatment
  • Cancer Immunotherapy and Biomarkers
  • Ocular Oncology and Treatments
  • PARP inhibition in cancer therapy
  • Advanced Breast Cancer Therapies
  • Cancer Treatment and Pharmacology
  • Glioma Diagnosis and Treatment
  • Extracellular vesicles in disease
  • Cancer survivorship and care
  • Chronic Lymphocytic Leukemia Research
  • Advanced Radiotherapy Techniques
  • Cancer Cells and Metastasis
  • Immune cells in cancer
  • Breast Implant and Reconstruction
  • Head and Neck Surgical Oncology
  • Head and Neck Cancer Studies
  • BRCA gene mutations in cancer

Institut Curie
2016-2024

Université Paris Sciences et Lettres
2019-2023

Zimmer Biomet (France)
2020-2023

Singapore Immunology Network
2019-2022

Agency for Science, Technology and Research
2019-2022

Aix-Marseille Université
2019

Institut Bergonié
2017

Centre Léon Bérard
2017

Institut Claudius Regaud
2017

Centre Antoine Lacassagne
2017

Abstract Background Large-scale single-cell transcriptomic datasets generated using different technologies contain batch-specific systematic variations that present a challenge to batch-effect removal and data integration. With continued growth expected in scRNA-seq data, achieving effective batch integration with available computational resources is crucial. Here, we perform an in-depth benchmark study on correction methods determine the most suitable method for removal. Results We compare...

10.1186/s13059-019-1850-9 article EN cc-by Genome biology 2020-01-16

Concurrent chemoradiotherapy (CRT) with blockade of the PD-1 pathway may enhance immune-mediated tumor control through increased phagocytosis, cell death, and antigen presentation. The NiCOL phase 1 trial (NCT03298893) is designed to determine safety/tolerance profile recommended phase-II dose nivolumab following concurrent CRT in 16 women locally advanced cervical cancer. Secondary endpoints include objective response rate (ORR), progression free survival (PFS), disease survival, immune...

10.1038/s41467-023-39383-8 article EN cc-by Nature Communications 2023-06-22

The diversity of the naïve T cell repertoire drives replenishment potential and capacity memory cells to respond immune challenges. Attrition system is associated with an increased prevalence pathologies in aged individuals, but whether stem lymphocytes (T

10.1038/s41467-020-14442-6 article EN cc-by Nature Communications 2020-02-10

Advance care planning is essential to enable informed medical decisions be made and reduce aggressiveness in end-of-life (EOL) care.This study aimed explore whether a question prompt list (QPL) adapted French language culture could promote discussions, particularly on prognosis EOL issues, among advanced cancer patients attending outpatient palliative (PC) consultations.In this multicenter randomized study, assigned the intervention arm received QPL help them prepare for next consultation...

10.1016/j.jpainsymman.2020.07.026 article EN cc-by-nc-nd Journal of Pain and Symptom Management 2020-07-31

Langerhans cell histiocytosis (LCH) is a potentially fatal neoplasm characterized by the aberrant differentiation of mononuclear phagocytes, driven mitogen-activated protein kinase (MAPK) pathway activation. LCH cells may trigger destructive pathology yet remain in precarious state finely balanced between apoptosis and survival, supported unique inflammatory milieu. The interactions that maintain this are not well known offer targets for intervention. Here, we used single-cell RNA-seq...

10.1126/sciimmunol.add3330 article EN Science Immunology 2022-12-16

Abstract Using human hepatocellular carcinoma (HCC) tissue samples stained with seven immune markers including one nuclear counterstain, we compared and evaluated the use of a new dimensionality reduction technique called Uniform Manifold Approximation Projection (UMAP), as an alternative to t-Distributed Stochastic Neighbor Embedding (t-SNE) in analysing multiplex-immunofluorescence (mIF) derived single-cell data. We adopted unsupervised clustering algorithm FlowSOM identify eight major...

10.1101/549659 preprint EN bioRxiv (Cold Spring Harbor Laboratory) 2019-02-15

Clinically important broadly reactive B cells evolve during multiple infections, with re-activated after secondary infection differing from activated a primary infection. Here we studied CD27highCD38high plasmablasts patients or dengue virus Three transcriptionally and functionally distinct clusters were identified. The largest cluster 0/1 was plasma cell-related, coding for serotype cross-reactive antibodies of the IgG1 isotype, consistent memory cell activation an extrafollicular response....

10.1016/j.isci.2021.102482 article EN cc-by-nc-nd iScience 2021-04-29

Introduction Much drug development and published analysis for epithelial ovarian cancer (EOC) focuses on early-line treatment. Full sequences of treatment from diagnosis to death the impact later lines therapy are rarely studied. We describe establishment an international network centers configured compare real-world pathways in UK, Portugal, Germany, South Korea, France Romania (the Ovarian Real-World International Consortium; ORWIC). Methods 3344 patients diagnosed with EOC (2012-2018)...

10.3389/fonc.2023.1114435 article EN cc-by Frontiers in Oncology 2023-01-27

Short hairpin RNA ligands that activate RIG-I induce antiviral responses in infected cells and prevent or control viral infections. Here, we characterized a new short molecule with high efficacy gene activation showed this is able to dengue virus infection. We demonstrate how structural modifications of minimal can lead increased potency wider window RIG-I-activating concentrations before regulatory mechanisms kick at concentrations. also show an effective response human skin dendritic...

10.1128/jvi.00102-19 article EN cc-by Journal of Virology 2019-05-01

Abstract Background Retinoblastoma with macroscopic optic nerve (ON) invasion depicted by imaging at diagnosis remains a major problem and carries poor prognosis. We sought to describe the treatment outcome of these high‐risk patients. Methods Retrospective mono‐institutional clinical, radiological, histological review patients uni‐ or bilateral retinoblastoma obvious ON invasion, defined radiological enlargement (RONE) computed tomography scan magnetic resonance (MRI), was performed....

10.1002/pbc.27998 article EN Pediatric Blood & Cancer 2019-10-01

5534 Background: Current management of locally-advanced cervical cancers (LACC) relies on chemoradiotherapy (CRT) and brachytherapy. The causal relation between cancer human papillomavirus infection, which engenders tumor expression immunoreactive neo-antigens, together with high PD-L1 expression, warrants consideration immune checkpoint inhibitors (ICI) in the definitive treatment this disease. We assessed safety concurrent maintenance nivolumab addition to CRT patients LACC. Methods: This...

10.1200/jco.2022.40.16_suppl.5534 article EN Journal of Clinical Oncology 2022-06-01

Objective Treatment of high-grade serous ovarian carcinomas relies on surgery and chemotherapy, potentially followed by bevacizumab and/or poly (ADP-ribose) polymerase inhibitors (PARPi). The modeled CA-125 ELIMination rate constant K (KELIM) is a pragmatic indicator tumor primary chemosensitivity. Although it well established that BRCA mutations are associated with platinum sensitivity, the relationship between status KELIM score has yet to be elucidated. This study aimed evaluate...

10.1136/ijgc-2024-005815 article EN International Journal of Gynecological Cancer 2024-10-31

7566 Background: Results of conventional induction chemotherapies in PCNSL need to be improved. Ibrutinib, a BTK inhibitor, and lenalidomide, an immunomodulatory drug, have shown promising results the relapse setting, supporting further assess their combination with standard high-dose methotrexate-based chemotherapy. Methods: Patients (pts) newly diagnosed PCNSL, aged 18 60, were randomized receive four 28-day cycles either ibrutinib or lenalidomide R-MPV (rituximab, methotrexate,...

10.1200/jco.2023.41.16_suppl.7566 article EN Journal of Clinical Oncology 2023-06-01

<h3>Objective</h3> Chemotherapy for high-grade serous ovarian cancers in platinum-sensitive relapse includes carboplatin/paclitaxel, carboplatin/gemcitabine, and carboplatin/pegylated liposomal doxorubicin. According to <i>in vitro</i> data, <i>BRCA</i> mutated patients are sensitive replicative stress agents but status is not yet used the choice of chemotherapy at relapse. Our aim was assess these doublets according first <h3>Methods</h3> The ESME cancer database comprises a multicenter...

10.1136/ijgc-2022-003993 article EN cc-by-nc-nd International Journal of Gynecological Cancer 2023-01-11
Coming Soon ...